S&P 500
7,757.17
+44.60
+0.58%
Dow
52,856.09
+360.19
+0.69%
Nasdaq
26,702.86
+278.04
+1.05%
NYSE Composite
24,253.12
+62.52
+0.26%
Russell 2000
2,781.02
+7.60
+0.27%
VIX
16.68
-0.63
-3.64%
DARE · Dare Bioscience, Inc.
NASDAQ NMS - GLOBAL MARKET - BOATS Real Time Price • USD
Dare Bioscience Inc (DARE)
NASDAQ NMS - GLOBAL MARKET
Pharmaceuticals
$0.68
-0.03
(-4.00%)
● At close: October 20 at 4:00:00 PM EDT
DAY'S RANGE
$0.68
$0.68
$0.69
52-WEEK RANGE
$0.68
$0.67
$3.78
What's happening
- DARE is down 4.00% today, trading at $0.68. — Live quote
- It's trading within 3% of its 52-week low ($0.67). (Finnhub fundamentals)
- Volume today (5,288) is well below its 3-month average of 414,750. (Finnhub fundamentals)
- Reports earnings on 2026-11-11, 20 days away. (Finnhub earnings calendar)
- Last quarter's EPS beat estimates: $-0.20 actual vs. $-0.25 estimated (+20.0%). (Finnhub earnings history)
Deterministic template sentences filled in from the same sourced figures shown elsewhere on this page -- not an AI-written summary, no live model call.
Key Statistics
Analyst Recommendations
Strong buy 2
Buy 6
Hold 1
Sell 0
Strong sell 0
Aggregate ratings for 2026-10-01 (9 analysts polled by Finnhub) — consensus count.
Performance Overview (Trailing returns vs S&P 500 benchmark)
YTD RETURN
DARE
-64.30%
vs S&P 500
-77.08%
1-YEAR RETURN
DARE
-66.39%
vs S&P 500
-80.95%
6-MONTH RETURN
DARE
-74.67%
3-MONTH RETURN
DARE
-44.88%
Earnings Trends (Quarterly EPS Actual vs Estimate)
2026-07-26 (Q2 2026)
$-0.20
Est. $-0.25
BEAT +20.0%
2026-04-26 (Q1 2026)
$-0.20
Est. $-0.30
BEAT +32.4%
2026-01-26 (Q4 2025)
$-0.02
Est. $-0.44
BEAT +95.5%
2025-10-26 (Q3 2025)
$-0.28
Est. $-0.36
BEAT +23.0%
Valuation Measures & Ratios
Enterprise Value4$6.7M
Forward P/E5—
PEG Ratio6—
Price / Sales (TTM1)9.79
Price / Book736.08
EV4 / Revenue4.87
EV4 / EBITDA—
Profit Margin-804.36%
Operating Margin-813.37%
Return on Equity (ROE8)-373.17%
Return on Assets (ROA9)-38.75%
Avg Volume (3M)414,750
Quarterly history (5 periods)
| Measure | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 |
|---|---|---|---|---|---|
| Market cap | $21.0M | $17.3M | $17.9M | $9.0M | $8.4M |
| P/E | -1.55 | -1.16 | -1.07 | -48.14 | -2.87 |
| Price/Sales | — | — | — | — | 85.03 |
| Price/Book | -37.46 | 23.60 | 6.25 | -0.71 | -0.88 |
| EV/Revenue | — | — | — | — | -18.53 |
| EV/EBITDA | -0.73 | 0.09 | 0.33 | — | — |
| ROE | 2421.34% | -2036.55% | -582.95% | 1.47% | 30.59% |
| ROA | -60.63% | -53.75% | -54.18% | -1.44% | -15.71% |
Trailing-twelve-month ratios computed from SEC EDGAR quarterly figures and historical daily close prices (Alpaca). Diluted shares are derived from Net income ÷ EPS (diluted) for each quarter, not separately reported. Forward P/E/PEG unavailable (no free data source).
Glossary — what these abbreviations mean
- 1. TTM
- Trailing twelve months — the sum of the last four reported quarters, not a calendar year or the single latest quarter.
- 2. EPS
- Earnings per share — net income divided by diluted shares outstanding.
- 3. Beta
- A stock's historical volatility relative to the overall market. Above 1 means it has moved more than the market; below 1, less.
- 4. EV (Enterprise Value)
- Market cap plus total debt minus cash — roughly what it would cost to buy the whole company, debt included.
- 5. Forward P/E
- Price divided by analysts' estimated earnings for the next 12 months, instead of trailing actual earnings.
- 6. PEG Ratio
- P/E divided by expected earnings growth rate. A lower number can indicate a stock is cheap relative to how fast it's expected to grow.
- 7. Price / Book
- Share price divided by book value (assets minus liabilities) per share.
- 8. ROE
- Return on equity — net income divided by shareholders' equity, a measure of how efficiently a company turns equity into profit.
- 9. ROA
- Return on assets — net income divided by total assets, a measure of how efficiently a company turns assets into profit.
- 10. MRQ
- Most recent quarter — the single latest reported period, as opposed to TTM. The Financials section's "Quarterly" view below shows MRQ-style figures.
- 11. YoY
- Year over year — percent change versus the same period one year earlier, used for growth figures like those on Compare cards and the Screener.
Short Interest
Shares Short922,037
Change from Prior Settlement+7.31%
% of Float—
Days to Cover (Short Ratio)3.08
Source: FINRA Rule 4560 consolidated short interest, settlement date 2026-09-30. Reported bi-monthly with a reporting lag — not real-time.
Quotes and the 1-day extended-hours chart: Yahoo Finance. Longer historical charts: Alpaca (IEX feed) — real-time but IEX-only volume (~2.5% of consolidated market volume). Fundamentals + earnings: Finnhub.
Price history
Events
Drag horizontally to zoom into a section; use Reset view to restore all observations.
Technical signal summary
Calculating from the latest year of daily price history…
Show Technical Analysis Breakdown ▾ 10 Indicators
Not investment advice — read several signals together.
Indicators None active
Loading chart…
History limited by data provider; markers are heuristics, not signals.
Peer and sector context
No reviewed peer group is available for this symbol.
Balanced evidence
A deterministic summary of sourced facts—not an AI verdict.
Potential strengths
- Revenue growth is 499.5% on the provider's reported measure. Finnhub fundamentals ↗
- Latest SEC filing is Form 8-K, filed 2026-10-02; review it for current changes and risks. SEC EDGAR ↗
Potential concerns
- Net profit margin is -804.4%. Finnhub fundamentals ↗
- Trailing 52-week price return is -66.4%. Finnhub market metrics ↗
Rule-based facts only; absence from either side is not evidence, and this is not a recommendation.
More on DARE
No accessible free API for these — links go to the source directly.
Financials
Fundamental trends
Visualized from the same SEC figures in the tables below.
Income statement
| Line item | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 | Sep '24 | Jun '24 | Mar '24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $187.5K | $152.5K | $2.3K | — | $25.4K | $41.7K | $22.4K | $9.3K |
| Operating income | -$3.0M | -$3.0M | -$3.7M | -$3.8M | -$4.6M | -$4.7M | -$7.4M | -$6.0M |
| Net income | -$3.0M | -$3.0M | -$3.6M | -$4.0M | -$4.4M | -$4.7M | $12.9M | -$6.8M |
| EPS (diluted) | $-0.20 | $-0.21 | $-0.28 | $-0.45 | $-0.50 | $-0.55 | $1.52 | $-0.81 |
| EPS (basic) | $-0.20 | $-0.21 | $-0.28 | $-0.45 | $-0.50 | $-0.55 | $1.53 | $-0.81 |
| Operating margin | -$1.6K | -$2.0K | -$162.3K | — | -$18.0K | -$11.2K | -$32.8K | -$64.7K |
| Net margin | -$1.6K | -$2.0K | -$157.5K | — | -$17.2K | -$11.3K | $57.5K | -$72.6K |
Balance sheet
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Total assets | $22.4M | $27.8M | $32.5M | $30.7M | $13.0M | $18.6M | $22.1M | $18.1M |
| Total liabilities | $22.9M | $27.1M | $29.6M | $27.9M | $25.7M | $28.2M | $28.1M | $19.5M |
| Stockholders' equity | -$560.1K | $734.5K | $2.8M | $2.9M | -$12.7M | -$9.6M | -$6.0M | -$1.5M |
| Total current assets | $16.7M | $21.7M | $27.1M | $25.0M | $6.6M | $11.8M | $18.4M | $14.9M |
| Total current liabilities | $16.9M | $21.1M | $23.7M | $21.2M | $19.2M | $21.2M | $21.6M | $13.2M |
| Cash & equivalents | $12.6M | $18.5M | $24.7M | $23.1M | $5.0M | $10.3M | $15.7M | $11.2M |
| Accounts receivable | — | — | — | — | — | — | — | — |
| Other current assets | $456.4K | $687.8K | $573.1K | $53.2K | — | — | $0 | — |
| Property, plant & equipment | $1.4M | $1.4M | $1.6M | $1.7M | $1.7M | $1.5M | $1.3M | $706.3K |
| Goodwill | — | — | — | — | — | — | — | — |
| Other non-current assets | $2.6M | $2.4M | $1.0M | $1.0M | $1.1M | $1.1M | $1.1M | $533.9K |
| Accounts payable | $762.9K | $1.2M | $1.2M | $1.8M | $1.8M | $1.9M | $1.5M | $1.0M |
| Accrued liabilities | $448.9K | $529.3K | $725.2K | $2.3M | $2.5M | $1.8M | $3.0M | $1.9M |
| Deferred revenue (current) | — | — | — | — | — | — | — | — |
| Short-term debt | — | — | — | $10.5K | $188.0K | $91.9K | $4.1K | — |
| Other current liabilities | — | — | — | — | — | — | — | — |
| Other non-current liabilities | — | — | — | — | — | — | — | — |
| Common stock & paid-in capital | $1.5K | $1.5K | $1.4K | $1.4K | $903 | $885 | $870 | $854 |
| Retained earnings | -$194.7M | -$191.7M | -$188.7M | -$187.2M | -$183.7M | -$179.7M | -$175.3M | -$169.8M |
| Accumulated other comprehensive income (loss) | -$374.9K | -$377.1K | -$421.6K | -$396.0K | -$402.8K | -$415.7K | -$428.8K | -$362.6K |
Cash flow
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$6.8M | -$5.5M | $1.4M | -$442.1K | -$5.4M | -$5.5M | $5.3M | -$5.9M |
| Investing cash flow | -$80.6K | $0 | -$206.6K | -$174.7K | $153.4K | -$157.3K | -$562.8K | $282.3K |
| Financing cash flow | $951.2K | -$715.5K | $424.1K | $18.7M | -$43.8K | $246.6K | -$211.3K | $436.4K |
| Free cash flow | -$6.9M | -$5.5M | $1.2M | -$616.8K | -$5.3M | -$5.6M | $4.7M | -$5.6M |
| Capital expenditures | $80.6K | $0 | $206.6K | $174.7K | -$153.4K | $157.3K | $562.8K | -$282.3K |
| Depreciation & amortization | $572.1K | $554.6K | $534.4K | $470.3K | $454.2K | $175.6K | $6.4K | $9.7K |
| Share-based compensation | $286.6K | $455.1K | $357.2K | $403.0K | $359.0K | $377.4K | $489.3K | $523.6K |
| Change in accounts receivable | -$123.8K | $120.6K | $12.1K | — | $0 | $0 | -$28.0K | — |
| Change in accounts payable | — | — | -$255.1K | — | — | — | -$1.9M | — |
Income statement
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Revenue | $1.0M | $9.8K | $2.8M | $10.0M | $0 |
| Operating income | -$13.6M | -$23.5M | -$30.9M | -$31.4M | -$39.1M |
| Net income | -$13.4M | -$4.1M | -$30.2M | -$30.9M | -$38.7M |
| EPS (diluted) | $-1.20 | $-0.48 | $-4.15 | $-0.37 | $-0.63 |
| EPS (basic) | $-1.20 | $-0.48 | $-4.15 | $-0.37 | $-0.63 |
| Operating margin | -$1.3K | -$239.7K | -$1.1K | -$314 | — |
| Net margin | -$1.3K | -$41.4K | -$1.1K | -$309 | — |
Balance sheet
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Total assets | $32.5M | $22.1M | $21.3M | $43.8M | $55.8M |
| Total liabilities | $29.6M | $28.1M | $26.3M | $32.7M | $17.1M |
| Stockholders' equity | $2.8M | -$6.0M | -$5.0M | $11.1M | $38.8M |
| Total current assets | $27.1M | $18.4M | $17.5M | $43.0M | $55.3M |
| Total current liabilities | $23.7M | $21.6M | $20.5M | $31.6M | $16.1M |
| Cash & equivalents | $24.7M | $15.7M | $10.5M | $34.7M | $51.7M |
| Other current assets | — | — | — | — | — |
| Property, plant & equipment | $1.6M | $1.3M | $656.0K | $64.9K | $26.0K |
| Goodwill | — | — | — | — | — |
| Other non-current assets | $1.0M | $1.1M | $599.6K | $254.3K | $485.1K |
| Accounts payable | $1.2M | $1.5M | $3.4M | $2.0M | $2.1M |
| Accrued liabilities | $725.2K | $3.0M | $2.9M | $10.9M | $3.1M |
| Other current liabilities | — | — | — | — | — |
| Other non-current liabilities | — | — | — | — | $0 |
| Common stock & paid-in capital | $1.4K | $870 | $833 | $8.5K | $8.4K |
| Retained earnings | -$188.7M | -$175.3M | -$171.2M | -$141.1M | -$110.1M |
| Accumulated other comprehensive income (loss) | -$421.6K | -$428.8K | -$360.9K | -$351.3K | -$155.0K |
Cash flow
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Operating cash flow | -$9.9M | $5.5M | -$38.9M | -$18.1M | -$28.8M |
| Investing cash flow | -$385.3K | -$573.0K | -$629.4K | -$63.1K | -$14.5K |
| Financing cash flow | $19.3M | $354.5K | $15.6M | $1.3M | $75.8M |
| Free cash flow | -$10.3M | $4.9M | -$39.5M | -$18.2M | -$28.8M |
| Capital expenditures | $385.3K | $573.0K | $629.4K | $63.1K | $14.5K |
| Depreciation & amortization | $1.6M | $42.3K | — | — | — |
| Share-based compensation | $1.5M | $2.2M | $2.5M | $2.2M | $1.6M |
| Change in accounts receivable | $12.1K | $0 | — | — | — |
| Change in accounts payable | -$255.1K | -$1.9M | $1.4M | -$75.1K | $1.1M |
Source: SEC EDGAR XBRL filings (10-Q/10-K), as originally tagged by the company. Quarterly cash flow is reconstructed by de-cumulating fiscal-year-to-date figures (how cash flow is tagged in 10-Qs); other quarterly lines are reported directly.
Institutional holders
SEC Form 13F filers holding DARE as of the latest reported quarter. 13F only covers investment managers with $100M+ in assets — this is not a complete ownership picture, and does not include insiders (see Recent SEC filings below) or non-13F-eligible holders.
Institutional ownership is not available for this symbol right now.
Insider activity
Directors, officers, and 10%+ owners' reported transactions from SEC Form 4. A filing reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR Form 4 filings · checked 25 most recent filings · covers 2026-06-30 to 2026-06-30
Recent transactions
- Most recent: Grossman Jessica D. (Director) — Grant / award of 26,066 shares on 2026-06-30.
Deterministic template sentences filled in from the SEC Form 4 figures in the tables below -- not an AI-written summary, no live model call.
Insider purchases & sales, last 6 months
Purchases (open market)0 sh(0 txns)
Sales (open market)0 sh(0 txns)
Net Shares+0
Counts only open-market purchases (code P) and sales (code S) — grants, option exercises, tax withholding, and gifts are excluded since they aren't a market buy/sell decision.
Insider roster
| Name | Title | Most Recent Transaction | Date | Shares |
|---|---|---|---|---|
| Grossman Jessica D. | Director | Grant / award | 2026-06-30 | 26,066 |
| Kelley Susan L. | Director | Grant / award | 2026-06-30 | 23,696 |
| Matz Gregory W | Director | Grant / award | 2026-06-30 | 30,805 |
| RASTETTER WILLIAM H | Director | Grant / award | 2026-06-30 | 38,862 |
| Steele Robin Joan | Director | Grant / award | 2026-06-30 | 26,540 |
Recent transactions
| Date | Insider | Title | Transaction | Shares | Price |
|---|---|---|---|---|---|
| 2026-06-30 | Grossman Jessica D. | Director | Grant / award | 26,066 | $0.00 |
| 2026-06-30 | Kelley Susan L. | Director | Grant / award | 23,696 | $0.00 |
| 2026-06-30 | Matz Gregory W | Director | Grant / award | 30,805 | $0.00 |
| 2026-06-30 | RASTETTER WILLIAM H | Director | Grant / award | 38,862 | $0.00 |
| 2026-06-30 | Steele Robin Joan | Director | Grant / award | 26,540 | $0.00 |
Recent SEC filings
Official company reports and insider transaction filings. Form 4 reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR submissions · updated 2026-10-21 23:20 UTC
| Filed | Form | Report period | Official filing |
|---|---|---|---|
| 2026-10-02 | 8-K | 2026-09-28 | View on SEC.gov → |
| 2026-10-01 | 8-K | 2026-10-01 | View on SEC.gov → |
| 2026-09-11 | 8-K | 2026-09-10 | View on SEC.gov → |
| 2026-09-09 | 8-K | 2026-09-09 | View on SEC.gov → |
| 2026-08-17 | 8-K | 2026-08-14 | View on SEC.gov → |
| 2026-08-13 | 8-K | 2026-08-13 | View on SEC.gov → |
| 2026-08-13 | 10-Q | 2026-06-30 | View on SEC.gov → |
| 2026-07-24 | 8-K | 2026-07-24 | View on SEC.gov → |
| 2026-07-17 | 8-K | 2026-07-13 | View on SEC.gov → |
| 2026-07-13 | 8-K | 2026-07-13 | View on SEC.gov → |
| 2026-07-02 | 4 | 2026-06-30 | View on SEC.gov → |
| 2026-07-02 | 4 | 2026-06-30 | View on SEC.gov → |
Recent news
Headlines about DARE (Dare Bioscience, Inc.). Links open the publisher — we don’t host full articles.
-
Quote of the Day by Anant Ambani: 'My grandfather said, 'Dare to dream', so I dreamt and made it a reality'
Business Today · 2026-10-21 -
'Would anyone dare to behave like that with Coldplay?': Mika Singh defends Daler Mehndi after Uttarakhand
The Times of India · 2026-10-20 -
Without Tinubu's policies, Dangote Refinery wouldn't have succeeded - Dare Watch full interview: https://youtu.be/dThx3VmM5FM #trusttvnews #Dangote #DangoteRefinery #Tinubu #TinubuReforms #SundayDare #Subsidy
Instagram · 2026-10-19 -
Daré Bioscience Sponsors HERmedicine Educational Program for Clinicians on Managing Menopause After Breast Cancer
Yahoo · 2026-10-19 -
Consideration is being given to transferring EVN, PVN, and TKV to the Ministry of Industry and Trade; Chairman Duc 'doesn't dare take the risk anymore'.
Vietnam.vn · 2026-10-18 -
Dare County encourages preparedness for residents, visitors and businesses ahead of potential coastal storm impacts
Island Free Press · 2026-10-16 -
'How Dare You Talk to Me Like This': IAS Officer Abuses Female Officer During Virtual Meeting; Video Goes...
Lokmat Times · 2026-10-16 -
Daré Bioscience Launches “CEO Corner” Video Series to Highlight the Company’s Pipeline of Women’s Health Innovations, Corporate Strategy and Opportunities
Yahoo · 2026-10-13
No headlines in this category right now — try “All”.